| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.0093 | 0.8 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | -0.0083 | 0.8 |
| mRNA | Tipifarnib | GDSC1000 | pan-cancer | AAC | -0.0084 | 0.8 |
| mRNA | YK 4-279 | GDSC1000 | pan-cancer | AAC | 0.0086 | 0.8 |
| mRNA | GSK2126458 | GDSC1000 | pan-cancer | AAC | -0.0075 | 0.8 |
| mRNA | BRD-K48334597 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.8 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.8 |
| mRNA | KU-60019 | CTRPv2 | pan-cancer | AAC | 0.0081 | 0.8 |
| mRNA | BRD-K16147474 | CTRPv2 | pan-cancer | AAC | -0.0091 | 0.8 |